-
公开(公告)号：US10683290B2
公开(公告)日：2020-06-16
申请号：US15573141
申请日：2016-05-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Claude A. Quesnelle , Lalgudi S. Harikrishnan , Matthew D. Hill
IPC: C07D471/04 , A61P35/02
Abstract: The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
-
公开(公告)号：US20180127413A1
公开(公告)日：2018-05-10
申请号：US15573141
申请日：2016-05-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Claude A. QUESNELLE , Lalgudi S. Harikrishnan , Matthew D. Hill
IPC: C07D471/04 , A61P35/02
Abstract: The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
-
公开(公告)号：US09725449B2
公开(公告)日：2017-08-08
申请号：US15150492
申请日：2016-05-10
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Derek J. Norris , Wayne Vaccaro , Mikkel V. DeBenedetto , Andrew P. Degnan , George V. Delucca , Jeffrey A. Deskus , Wen-Ching Han , Godwin Kwame Kumi , William D. Schmitz , John E. Starrett, Jr. , Matthew D. Hill , Hong Huang
IPC: C07D471/14 , A61K31/4375 , A61K31/439 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/519 , A61K31/5377 , A61K31/541 , A61K31/554 , A61K31/675 , A61K31/683 , C07D519/00 , C07F9/6561
CPC classification number: C07D471/14 , A61K31/4375 , A61K31/439 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/519 , A61K31/5377 , A61K31/541 , A61K31/554 , A61K31/675 , A61K31/683 , C07D519/00 , C07F9/6561
Abstract: The present invention is directed to tricyclic compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
-
![QUINUCLIDINE, 1-AZABICYCLO[2.2.1]HEPTANE, 1-AZABICYCLO [3.2.1]OCTANE, and 1-AZABICYCLO[3.2.2]NONANE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS](/abs-image/US/2015/11/12/US20150322089A1/abs.jpg.150x150.jpg)
4.发明申请QUINUCLIDINE, 1-AZABICYCLO[2.2.1]HEPTANE, 1-AZABICYCLO [3.2.1]OCTANE, and 1-AZABICYCLO[3.2.2]NONANE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS 有权喹诺酮，1-氮杂环丁酮[2.2.1]庚二酸，1-亚氨基半胱氨酸[3.2.1]月桂酸和1-亚氨基半胱氨酸[3.2.2] NONANE化合物作为ALPHA-7 NICOTINIC乙酰胆碱受体配体公开(公告)号：US20150322089A1
公开(公告)日：2015-11-12
申请号：US14400948
申请日：2013-05-20
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Matthew D. Hill , Haiquan Fang
IPC: C07D519/00 , C07D498/20 , C07D471/20
CPC classification number: C07D519/00 , C07D453/02 , C07D471/20 , C07D498/20
Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.
Abstract translation: 本公开提供式I化合物，包括其盐，以及使用该化合物的组合物和方法。 这些化合物是烟碱型α7受体的配体，可用于治疗中枢神经系统的各种疾病，特别是情感和神经退行性疾病。
-
公开(公告)号：US11166959B2
公开(公告)日：2021-11-09
申请号：US16761449
申请日：2018-11-05
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Erika M. V. Araujo , Yan Chen , Bireshwar Dasgupta , Andrew P. Degnan , Matthew D. Hill , Godwin Kwame Kumi , Harold A. Mastalerz , Mark D. Wittman , Bradley C. Pearce , Guifen Zhang
IPC: A61K31/5377 , A61K31/506 , A61P35/00 , A61K45/06 , C07D405/12 , C07D405/14 , C07D413/14 , C07D453/02 , C07D491/048 , C07D498/10 , C07D519/00
Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is CH or N; Y is CR5 or N; and R1, R2, R3, R4, and R5 are defined herein. Also disclosed are methods of using such compounds to modulate or inhibit the enzymatic activity of hematopoietic progenitor kinase 1 (HPK1), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
-
Patent Agency Ranking
公开(公告)号：US10174052B2
公开(公告)日：2019-01-08
申请号：US15523416
申请日：2015-11-03
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： James H. Cook, II , F. Christopher Zusi , Matthew D. Hill
IPC: C07D498/22 , A61K31/439 , C07D498/10
Abstract: There are disclosed a series of quinuclidines having the Formula (I), which bind to the nicotinic α7 receptor and may be useful for the treatment of disorders of the central nervous system.
-
公开(公告)号：US09751879B2
公开(公告)日：2017-09-05
申请号：US15219611
申请日：2016-07-26
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Derek J. Norris , George V. Delucca , Ashvinikumar V. Gavai , Claude A. Quesnelle , Patrice Gill , Daniel O'Malley , Wayne Vaccaro , Francis Y. Lee , Mikkel V. DeBenedetto , Andrew P. Degnan , Haiquan Fang , Matthew D. Hill , Hong Huang , William D. Schmitz , John E. Starrett, Jr. , Wen-Ching Han , John S. Tokarski , Sunil Kumar Mandal
IPC: C07D471/04 , A61K31/437
CPC classification number: C07D471/04 , A61K31/437 , A61K45/06 , A61K2300/00
Abstract: The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
-
公开(公告)号：US20160333013A1
公开(公告)日：2016-11-17
申请号：US15150492
申请日：2016-05-10
Applicant: Bristol-Myers Squibb Company
Inventor： Derek J. Norris , Wayne Vaccaro , Mikkel V. DeBenedetto , Andrew P. Degnan , George V. Delucca , Jeffrey A. Deskus , Wen-Ching Han , Godwin Kwame Kumi , William D. Schmitz , John E. Starrett, JR. , Matthew D. Hill , Hong Huang
IPC: C07D471/14 , A61K31/5377 , A61K31/496 , A61K31/444 , A61K31/541 , A61K31/675 , A61K31/4545 , C07D519/00 , A61K31/439 , A61K31/554 , C07F9/6561 , A61K31/683 , A61K31/4375 , A61K31/519
CPC classification number: C07D471/14 , A61K31/4375 , A61K31/439 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/519 , A61K31/5377 , A61K31/541 , A61K31/554 , A61K31/675 , A61K31/683 , C07D519/00 , C07F9/6561
Abstract: The present invention is directed to tricyclic compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
Abstract translation: 其中所有取代基在本文中定义，以及包含本发明化合物的药学上可接受的组合物以及使用所述组合物治疗各种疾病的方法。
-
公开(公告)号：US20160326173A1
公开(公告)日：2016-11-10
申请号：US15219611
申请日：2016-07-26
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Derek J. Norris , George V. Delucca , Ashvinikumar V. Gavai , Claude A. Quesnelle , Patrice Gill , Daniel O'Malley , Wayne Vaccaro , Francis Y. Lee , Mikkel V. DeBenedetto , Andrew P. Degnan , Haiquan Fang , Matthew D. Hill , Hong Huang , William D. Schmitz , John E. Starrett, JR. , Wen-Ching Han , John S. Tokarski , Sunil Kumar Mandal
IPC: C07D471/04 , A61K31/437
CPC classification number: C07D471/04 , A61K31/437 , A61K45/06 , A61K2300/00
Abstract: The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
Abstract translation: 本发明涉及三环化合物，包含本发明化合物的药学上可接受的组合物和使用所述组合物治疗各种疾病的方法。
-
![Quinuclidine, 1-azabicyclo[2.2.1]heptane, 1-azabicyclo [3.2.1]octane, and 1-azabicyclo[3.2.2]nonane compounds as alpha-7 nicotinic acetylcholine receptor ligands](/abs-image/US/2016/10/04/US09458179B2/abs.jpg.150x150.jpg)
10.发明授权Quinuclidine, 1-azabicyclo[2.2.1]heptane, 1-azabicyclo [3.2.1]octane, and 1-azabicyclo[3.2.2]nonane compounds as alpha-7 nicotinic acetylcholine receptor ligands 有权奎宁环，1-氮杂双环[2.2.1]庚烷，1-氮杂双环[3.2.1]辛烷和1-氮杂双环[3.2.2]壬烷化合物，为α-7烟碱乙酰胆碱受体配体公开(公告)号：US09458179B2
公开(公告)日：2016-10-04
申请号：US14400948
申请日：2013-05-20
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Matthew D. Hill , Haiquan Fang
IPC: C07D519/00 , C07D471/20 , C07D453/02 , C07D498/20
CPC classification number: C07D519/00 , C07D453/02 , C07D471/20 , C07D498/20
Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.
-
-
-
-
-
-
-
-
-
Search Results
15
records
(took 0.051 seconds)
